Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06607185 · ClinicalTrials.gov registry record · Phase 1
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
A Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 1
- Development phase
- 750
- Enrollment target
- 20
- Study locations
NCT06607185 is a Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 750 participants, above the 657-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (14% higher). The trial reports 20 study locations across 16 states.
The verdict
NCT06607185, a Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 750 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of the study is to assess whether the study drug, LY4066434, is safe and tolerable when administered to participants with locally advanced or metastatic solid tumors with certain KRAS mutations. LY4066434 will be given alone or in combination with other treatments. The study will have 2 parts: monotherapy dose escalation and dose optimization. The study is expected to last up to approximately 5 years.
Conditions Studied
Interventions
- DRUG Oxaliplatin
- DRUG Cetuximab
- DRUG Gemcitabine
- DRUG Nab paclitaxel
- DRUG LY4066434.
Study Locations (20)
California
- City of Hope - Duarte
- University of California, Los Angeles (UCLA) - Los Angeles
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Michigan
- Henry Ford Health System - Detriot
- South Texas Accelerated Research Therapeutics (START) Midwest - Grand Rapids
New York
- Columbia University - New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center - New York
Alabama
- University of Alabama at Birmingham - Birmingham
Arizona
- Mayo Clinic - Phoenix
Colorado
- University of Colorado Denver - Denver
Connecticut
- Yale University School of Medicine - Yale Cancer Center - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2024-10-21 |
| Est. Completion | 2030-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06607185
The ClinicalTrials.gov registry entry for NCT06607185 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 750 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 657-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (14% higher). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Oxaliplatin is the first listed.
NCT06607185 reports 20 study locations spanning 16 distinct geographic areas - top geographies include California, Massachusetts, Michigan.
Frequently Asked Questions
What is clinical trial NCT06607185 about?
NCT06607185 is a clinical study titled "A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors". The main purpose of the study is to assess whether the study drug, LY4066434, is safe and tolerable when administered to participants with locally advanced or metastatic solid tumors with certain KRAS mutations. LY4066434 will be given alone or in combination with other treatments. The study will ha...
What is the current status of trial NCT06607185?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 750 participants. The study started on 2024-10-21. Estimated completion is 2030-01.
What conditions does trial NCT06607185 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor, Pancreatic Ductal Adenocarcinoma, Metastatic Solid Tumor.
What interventions are being tested in trial NCT06607185?
The interventions under investigation include: Oxaliplatin (DRUG), Cetuximab (DRUG), Gemcitabine (DRUG), Nab paclitaxel (DRUG), LY4066434. (DRUG).
Who is sponsoring clinical trial NCT06607185?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06607185 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.